Cargando…

Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer

The androgen receptor (AR) is a key transcription factor in the initiation and progression of prostate cancer (PC) and is a major therapeutic target for the treatment of advanced disease. Unfortunately, current therapies are not curative for castration resistant PC and a better understanding of AR r...

Descripción completa

Detalles Bibliográficos
Autores principales: McClurg, Urszula L., Harle, Victoria J., Nabbi, Arash, Batalha-Pereira, Amanda, Walker, Scott, Coffey, Kelly, Gaughan, Luke, McCracken, Stuart RC, Robson, Craig N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741960/
https://www.ncbi.nlm.nih.gov/pubmed/26462181
_version_ 1782414109409542144
author McClurg, Urszula L.
Harle, Victoria J.
Nabbi, Arash
Batalha-Pereira, Amanda
Walker, Scott
Coffey, Kelly
Gaughan, Luke
McCracken, Stuart RC
Robson, Craig N.
author_facet McClurg, Urszula L.
Harle, Victoria J.
Nabbi, Arash
Batalha-Pereira, Amanda
Walker, Scott
Coffey, Kelly
Gaughan, Luke
McCracken, Stuart RC
Robson, Craig N.
author_sort McClurg, Urszula L.
collection PubMed
description The androgen receptor (AR) is a key transcription factor in the initiation and progression of prostate cancer (PC) and is a major therapeutic target for the treatment of advanced disease. Unfortunately, current therapies are not curative for castration resistant PC and a better understanding of AR regulation could identify novel therapeutic targets and biomarkers to aid treatment of this disease. The AR is known to be regulated by a number of post-translational modifications and we have recently identified the deubiquitinating enzyme Usp12 as a positive regulator of AR. We determined that Usp12 deubiquitinates the AR resulting in elevated receptor stability and activity. Furthermore, Usp12 silencing was shown to reduce proliferation of PC cells. Usp12 is known to require the co-factors Uaf-1 and WDR20 for catalytic activity. In this report we focus further on the role of Uaf-1 and WDR20 in Usp12 regulation and investigate if these co-factors are also required for controlling AR activity. Firstly, we confirm the presence of the Usp12/Uaf-1/WDR20 complex in PC cells and demonstrate the importance of Uaf-1 and WDR20 for Usp12 stabilisation. Consequently, we show that individual silencing of either Uaf-1 or WDR20 is sufficient to abrogate the activity of the Usp12 complex and down-regulate AR-mediated transcription via receptor destabilisation resulting in increased apoptosis and decreased colony forming ability of PC cells. Moreover, expression of both Uaf-1 and WDR20 is higher in PC tissue compared to benign controls. Overall these results highlight the potential importance of the Usp12/Uaf-1/WDR20 complex in AR regulation and PC progression. Androgen receptor is a key transcriptional regulator in prostate cancer. Usp12/Uaf-1/WDR20 complex plays a crucial role in androgen receptor stability and activity. Destabilising an individual Usp12/Uaf-1/WDR20 complex member reduces the protein levels of the whole complex and diminishes androgen receptor activity. Protein levels of all members of the Usp12/Uaf-1/WDR20 complex are significantly increased in PC;
format Online
Article
Text
id pubmed-4741960
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47419602016-03-17 Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer McClurg, Urszula L. Harle, Victoria J. Nabbi, Arash Batalha-Pereira, Amanda Walker, Scott Coffey, Kelly Gaughan, Luke McCracken, Stuart RC Robson, Craig N. Oncotarget Research Paper The androgen receptor (AR) is a key transcription factor in the initiation and progression of prostate cancer (PC) and is a major therapeutic target for the treatment of advanced disease. Unfortunately, current therapies are not curative for castration resistant PC and a better understanding of AR regulation could identify novel therapeutic targets and biomarkers to aid treatment of this disease. The AR is known to be regulated by a number of post-translational modifications and we have recently identified the deubiquitinating enzyme Usp12 as a positive regulator of AR. We determined that Usp12 deubiquitinates the AR resulting in elevated receptor stability and activity. Furthermore, Usp12 silencing was shown to reduce proliferation of PC cells. Usp12 is known to require the co-factors Uaf-1 and WDR20 for catalytic activity. In this report we focus further on the role of Uaf-1 and WDR20 in Usp12 regulation and investigate if these co-factors are also required for controlling AR activity. Firstly, we confirm the presence of the Usp12/Uaf-1/WDR20 complex in PC cells and demonstrate the importance of Uaf-1 and WDR20 for Usp12 stabilisation. Consequently, we show that individual silencing of either Uaf-1 or WDR20 is sufficient to abrogate the activity of the Usp12 complex and down-regulate AR-mediated transcription via receptor destabilisation resulting in increased apoptosis and decreased colony forming ability of PC cells. Moreover, expression of both Uaf-1 and WDR20 is higher in PC tissue compared to benign controls. Overall these results highlight the potential importance of the Usp12/Uaf-1/WDR20 complex in AR regulation and PC progression. Androgen receptor is a key transcriptional regulator in prostate cancer. Usp12/Uaf-1/WDR20 complex plays a crucial role in androgen receptor stability and activity. Destabilising an individual Usp12/Uaf-1/WDR20 complex member reduces the protein levels of the whole complex and diminishes androgen receptor activity. Protein levels of all members of the Usp12/Uaf-1/WDR20 complex are significantly increased in PC; Impact Journals LLC 2015-10-10 /pmc/articles/PMC4741960/ /pubmed/26462181 Text en Copyright: © 2015 McClurg et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
McClurg, Urszula L.
Harle, Victoria J.
Nabbi, Arash
Batalha-Pereira, Amanda
Walker, Scott
Coffey, Kelly
Gaughan, Luke
McCracken, Stuart RC
Robson, Craig N.
Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
title Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
title_full Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
title_fullStr Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
title_full_unstemmed Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
title_short Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
title_sort ubiquitin-specific protease 12 interacting partners uaf-1 and wdr20 are potential therapeutic targets in prostate cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741960/
https://www.ncbi.nlm.nih.gov/pubmed/26462181
work_keys_str_mv AT mcclurgurszulal ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer
AT harlevictoriaj ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer
AT nabbiarash ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer
AT batalhapereiraamanda ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer
AT walkerscott ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer
AT coffeykelly ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer
AT gaughanluke ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer
AT mccrackenstuartrc ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer
AT robsoncraign ubiquitinspecificprotease12interactingpartnersuaf1andwdr20arepotentialtherapeutictargetsinprostatecancer